CY1112393T1 - Παραγοντες για την αντιμετωπιση γλαυκωματικης αμφιβληστροειδοπαθειας και οπτικης νευροπαθειας - Google Patents

Παραγοντες για την αντιμετωπιση γλαυκωματικης αμφιβληστροειδοπαθειας και οπτικης νευροπαθειας

Info

Publication number
CY1112393T1
CY1112393T1 CY20111101143T CY111101143T CY1112393T1 CY 1112393 T1 CY1112393 T1 CY 1112393T1 CY 20111101143 T CY20111101143 T CY 20111101143T CY 111101143 T CY111101143 T CY 111101143T CY 1112393 T1 CY1112393 T1 CY 1112393T1
Authority
CY
Cyprus
Prior art keywords
factors
treatment
glycomatic
ambossibility
nrf2
Prior art date
Application number
CY20111101143T
Other languages
English (en)
Inventor
Robert Landers
Iok-Hou Pang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1112393T1 publication Critical patent/CY1112393T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Παράγοντες οι οποίοι διεγείρουν την πυρηνική μετατόπιση της Nrf2 πρωτεΐνης και τις επακόλουθες αυξήσεις γονιδιακών προϊόντων τα οποία αποτοξινώνουν και εξαλείφουν κυτταροτοξικούς μεταβολίτες παρέχονται σε μια μέθοδο για αντιμετώπιση γλαυκωματικής αμφιβληστροειδοπάθειας ή οπτικής νευροπάθειας. Οι δομικά ποικίλοι παράγοντες οι οποίοι δρουν στο Nrf2/ARE μονοπάτι επάγουν την έκφραση ενζύμων και πρωτεϊνών που έχουν χημικά ευπροσάρμοστες κυτταροπροστατευτικές ιδιότητες και είναι μια άμυνα ενάντια σε τοξικούς μεταβολίτες και ξενοβιοτικά. Οι παράγοντες περιλαμβάνουν ορισμένα ηλεκτρονιόφιλα και οξειδωτικά όπως έναν δέκτη προσθήκης Michael, διφαινόλη, θειοκαρβαμιδικό, κινόνη, 1,2-διθειολο-3-θειόνη, βουτυλιωμένη υδροξυανισόλη, φλαβονοειδές, ένα ισοθειοκυανικό, 3,5-δι-tert-βουτυλο-4-υδροξυτολουόλιο, αιθοξυκινίνη, μια κουμαρίνη, συνδυασμός αυτών, ή ένα φαρμακολογικώς δραστικό παράγωγο ή ανάλογο αυτών.
CY20111101143T 2003-12-22 2011-11-24 Παραγοντες για την αντιμετωπιση γλαυκωματικης αμφιβληστροειδοπαθειας και οπτικης νευροπαθειας CY1112393T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53177003P 2003-12-22 2003-12-22
EP07105047A EP1803468B1 (en) 2003-12-22 2004-12-17 Agents for treatment of glaucomatours retinopathy and optic neuropathy

Publications (1)

Publication Number Publication Date
CY1112393T1 true CY1112393T1 (el) 2015-12-09

Family

ID=34738696

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071100711T CY1106623T1 (el) 2003-12-22 2007-05-25 Παραγοντες για την αντιμετωπιση γλαυκωματικης αμφιβληστροειδοπαθειας και οπτικης νευροπαθειας
CY20111101143T CY1112393T1 (el) 2003-12-22 2011-11-24 Παραγοντες για την αντιμετωπιση γλαυκωματικης αμφιβληστροειδοπαθειας και οπτικης νευροπαθειας

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071100711T CY1106623T1 (el) 2003-12-22 2007-05-25 Παραγοντες για την αντιμετωπιση γλαυκωματικης αμφιβληστροειδοπαθειας και οπτικης νευροπαθειας

Country Status (20)

Country Link
US (2) US20050137146A1 (el)
EP (2) EP1803468B1 (el)
JP (2) JP4755599B2 (el)
KR (1) KR20060127043A (el)
CN (1) CN1897972A (el)
AT (2) ATE523208T1 (el)
AU (1) AU2004308919B2 (el)
BR (1) BRPI0417987A (el)
CA (1) CA2547852A1 (el)
CY (2) CY1106623T1 (el)
DE (1) DE602004005617T2 (el)
DK (2) DK1696958T3 (el)
ES (2) ES2371364T3 (el)
HK (2) HK1097179A1 (el)
MX (1) MXPA06006980A (el)
PL (2) PL1696958T3 (el)
PT (2) PT1803468E (el)
SI (2) SI1696958T1 (el)
WO (1) WO2005063295A1 (el)
ZA (1) ZA200604862B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881198B2 (en) * 2001-01-09 2005-04-19 J. David Brown Glaucoma treatment device and method
MXPA06006980A (es) * 2003-12-22 2006-12-14 Alcon Inc Agentes para tratamiento de retinopatia glaucomatosa y neuropatia optica.
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
JPWO2006030907A1 (ja) * 2004-09-16 2008-05-15 レドックス・バイオサイエンス株式会社 網膜保護剤
EP1924306A2 (en) * 2005-09-16 2008-05-28 BG Implant, Inc. Glaucoma treatment devices and methods
WO2008016095A1 (fr) * 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
CA2666461A1 (en) * 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
JP2008247898A (ja) * 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
TWI453023B (zh) 2008-04-18 2014-09-21 Reata Pharmaceuticals Inc 抗氧化發炎調節劑：在ｃ－１７處具有胺基及其他修飾之齊墩果酸衍生物
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
HUE033288T2 (en) 2008-04-18 2017-11-28 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives
JP5990160B2 (ja) 2010-04-12 2016-09-07 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーターを使用して肥満を処置する方法
RU2472475C2 (ru) * 2010-04-20 2013-01-20 Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) Способ комбинированного лечения глаукомной оптической нейропатии
WO2012009171A2 (en) * 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
RU2447864C1 (ru) * 2010-09-15 2012-04-20 Инна Витальевна Щербинина Способ лечения заболеваний зрительного нерва и сетчатки
WO2012177831A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Compounds for treating peripheral neuropathies and other neurodegenerative disorders
RU2546019C2 (ru) * 2013-03-02 2015-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения глаукомной оптической нейропатии
EP2991621B1 (en) 2013-05-02 2020-12-09 Retina Foundation of the Southwest Two-layer ocular implant
CA2972195A1 (en) 2014-12-31 2016-07-07 Microoptx Inc. Glaucoma treatment devices and methods
WO2017059272A1 (en) 2015-09-30 2017-04-06 Microoptx Inc. Dry eye treatment devices and methods
CN109996563A (zh) 2016-09-12 2019-07-09 St知识产权控股公司 4-甲基-5-(吡嗪-2-基)-3h-1,2-二硫杂环戊烯-3-硫酮的制剂、味道改良的制剂及其制备和使用方法
AU2017323504A1 (en) 2016-09-12 2019-05-02 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
RU2647324C1 (ru) * 2017-04-24 2018-03-15 Игорь Евгеньевич Хаценко Способ определения показаний для лечения амблиопии с помощью нейропептидного препарата
MX2022012209A (es) * 2020-03-30 2022-10-27 Wuhan Neurophth Biotechnology Ltd Company Vector de expresion del factor 2 relacionado con el factor nuclear humano e2 y aplicacion del vector de expresion.
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5571523A (en) * 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
AU689036B2 (en) * 1995-05-10 1998-03-19 Kureha Chemical Industry Co., Ltd. Pharmaceutical composition containing substance inhibiting HSP47 production
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5681854A (en) * 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
CN1155383C (zh) * 1995-12-21 2004-06-30 阿尔康实验室公司 某些异喹啉磺酰基化合物治疗青光眼及眼局部缺血的用途
CN1210521A (zh) * 1996-02-02 1999-03-10 日本新药株式会社 异喹啉衍生物及医药
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JP3872834B2 (ja) * 1996-03-04 2007-01-24 第一製薬株式会社 メイラード反応抑制剤
ATE359822T1 (de) * 1996-08-12 2007-05-15 Mitsubishi Pharma Corp Medikamente enthaltend rho-kinase inhibitoren
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
US5972923A (en) * 1997-01-16 1999-10-26 University Of Florida Research Foundation, Inc. Methods and compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
US6441033B1 (en) * 1997-12-22 2002-08-27 Alcon Manufacturing, Ltd. 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
AU2440599A (en) * 1998-02-25 1999-09-15 Shionogi & Co., Ltd. Therapeutic agent for complication of diabetes
US20010041174A1 (en) * 1998-11-24 2001-11-15 Najam Sharif Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases
US6020383A (en) * 1999-01-11 2000-02-01 Eastman Chemicals Company Method for reducing blood cholesterol and/or blood triglycerides
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
GB0030727D0 (en) * 2000-12-15 2001-01-31 Lumitech Uk Ltd Methods and kits for detecting kinase activity
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
CA2357265C (en) * 2001-04-24 2004-04-13 University Of British Columbia Improved additive for livestock feeds
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
US7199122B2 (en) * 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
EP1474158B1 (en) * 2001-12-18 2009-10-14 Brassica Foundation for Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase ii detoxification enzymes
EP1476143A1 (en) * 2002-02-15 2004-11-17 DSM IP Assets B.V. Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
US20030219846A1 (en) * 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
AU2003263988A1 (en) * 2002-08-05 2004-02-23 Wackvom, Ltd. Methods and compositions to treat conditions associated with neovascularization
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
BRPI0417996A (pt) * 2003-12-22 2007-04-27 Alcon Inc agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
MXPA06006980A (es) * 2003-12-22 2006-12-14 Alcon Inc Agentes para tratamiento de retinopatia glaucomatosa y neuropatia optica.

Also Published As

Publication number Publication date
CN1897972A (zh) 2007-01-17
KR20060127043A (ko) 2006-12-11
ATE357932T1 (de) 2007-04-15
MXPA06006980A (es) 2006-12-14
ES2371364T3 (es) 2011-12-30
CA2547852A1 (en) 2005-07-14
PT1803468E (pt) 2011-11-23
DK1803468T3 (da) 2011-12-05
WO2005063295A1 (en) 2005-07-14
ATE523208T1 (de) 2011-09-15
HK1097179A1 (en) 2007-06-22
EP1696958A1 (en) 2006-09-06
EP1696958B1 (en) 2007-03-28
HK1110772A1 (en) 2008-07-25
DE602004005617D1 (de) 2007-05-10
PL1696958T3 (pl) 2007-08-31
JP4755599B2 (ja) 2011-08-24
DK1696958T3 (da) 2007-07-09
JP2011046736A (ja) 2011-03-10
SI1803468T1 (sl) 2011-12-30
ES2282926T3 (es) 2007-10-16
PL1803468T3 (pl) 2012-05-31
AU2004308919A1 (en) 2005-07-14
SI1696958T1 (sl) 2007-08-31
US20050137146A1 (en) 2005-06-23
EP1803468A1 (en) 2007-07-04
CY1106623T1 (el) 2012-01-25
US20110144127A1 (en) 2011-06-16
JP2007515423A (ja) 2007-06-14
BRPI0417987A (pt) 2007-04-27
ZA200604862B (en) 2007-10-31
EP1803468B1 (en) 2011-09-07
DE602004005617T2 (de) 2007-12-13
PT1696958E (pt) 2007-06-04
AU2004308919B2 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
CY1112393T1 (el) Παραγοντες για την αντιμετωπιση γλαυκωματικης αμφιβληστροειδοπαθειας και οπτικης νευροπαθειας
CY1107181T1 (el) Συνδυασμος ζιζανιοκτονων με ακυλιωμενες αμινοφαινυλοσουλφονυλουριες
ES2161290T3 (es) Derivados de quinazolina.
GT200000014A (es) Derivados de quinolin - 2 - ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
BR0214750A (pt) Imidazoquinolinas tioéter substituìdas
NO981944L (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
DE602004008105D1 (de) 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen
BR0011448A (pt) Imidazoquinolinas substituìdas por amida
NO20034094D0 (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
CY1114397T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα
HK1059037A1 (en) Methods and compositions for treatment of ocular neovascularization and neural injury
DOP2006000141A (es) Derivados de oxindol
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY28691A1 (es) Derivados de difenilazetidona
BR0313767A (pt) Artigo de proteção da vida resistente à penetração
BRPI0417996A (pt) agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
ES2066914T3 (es) Factores a1, a2, a3 y h del antibiotico ge 2270.
ES2169022T3 (es) Utilizacion de derivados de (piridil-metil-sulfinil)-1-h-bencimidazol para el tratamiento de enfermedades provocadas por helicobacter.
ES2036238T3 (es) Derivados de hidroxietil-azolilo.
PT916670E (pt) Pirrolo-(3,2-b) piridinas e o seu uso como agonistas do 5-ht1f
AR034508A1 (es) Agente protector de las neuronas retinales.
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
ES2195439T3 (es) Glicosidos de antraciclina.